PE20121471A1 - Derivados de sulfonamida heterociclicos utiles como inhibidores de mek - Google Patents

Derivados de sulfonamida heterociclicos utiles como inhibidores de mek

Info

Publication number
PE20121471A1
PE20121471A1 PE2012000608A PE2012000608A PE20121471A1 PE 20121471 A1 PE20121471 A1 PE 20121471A1 PE 2012000608 A PE2012000608 A PE 2012000608A PE 2012000608 A PE2012000608 A PE 2012000608A PE 20121471 A1 PE20121471 A1 PE 20121471A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
helpful
heterocyclic sulfonamide
mek inhibitors
Prior art date
Application number
PE2012000608A
Other languages
English (en)
Inventor
Mark G Bock
Dinesh Chikkanna
Clive Mccarthy
Henrik Moebitz
Chetan Pandit
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43416908&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20121471A1 publication Critical patent/PE20121471A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE SULFONAMIDA HETEROCICLICO DE FORMULA (I) DONDE: R1a Y R1b SON HIDROXILO, CIANO, NITRO, ALQUILO C1-6, ALQUENILO C2-6, ENTRE OTROS; R2a ES H O ALQUILO C1-6; R2b ES ALQUILO C1-6, ALQUENILO C2-6, CICLOALQUILO, ARILO, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-6, ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO POR HALOGENO, HIDROXIALQUILO C1-6 O ALCOXILO C1-6, R5 ES H, HALOGENO, ALQUILO C1-3 O ALQUILO C1-3 SUSTITUIDO POR HALOGENO; X ES -N(R6)-; R6 ES H O ALQUILO C1-6; W ES NR22, O O S. R22 ES H, ALQUILO C1-6, ALQUENILO C2-6, CICLOALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [7-(4-BROMO-2-FLUORO-FENIL-AMINO)-6-METIL-5-OXO-1,2,3,5-TETRAHIDRO-IMIDAZO-[1,2-a]-PIRIDIN-8-IL]-AMIDA DEL ACIDO CICLOPROPAN-SULFONICO; [7-(2-FLUORO-4-YODO-FENIL-AMINO)-6-METIL-5-OXO-1,2,3,5-TETRAHIDRO-IMIDAZO-[1,2-a]-PIRIDIN-8-IL]-AMIDA DEL ACIDO 1-(2,3-DIHIDROXI-PROPIL)-CICLOPROPAN-SULFONICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DE LA PROTEINA CINASA DE MEK SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS COMO CANCER E INFLAMACION
PE2012000608A 2009-11-04 2010-11-02 Derivados de sulfonamida heterociclicos utiles como inhibidores de mek PE20121471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2678CH2009 2009-11-04

Publications (1)

Publication Number Publication Date
PE20121471A1 true PE20121471A1 (es) 2012-11-01

Family

ID=43416908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000608A PE20121471A1 (es) 2009-11-04 2010-11-02 Derivados de sulfonamida heterociclicos utiles como inhibidores de mek

Country Status (29)

Country Link
US (1) US8466289B2 (es)
EP (1) EP2496575B1 (es)
JP (1) JP5466767B2 (es)
KR (1) KR101398772B1 (es)
CN (1) CN102596951B (es)
AR (1) AR078900A1 (es)
AU (1) AU2010317167B2 (es)
BR (1) BR112012010519A2 (es)
CA (1) CA2779935A1 (es)
CL (1) CL2012001027A1 (es)
CO (1) CO6541547A2 (es)
CR (1) CR20120234A (es)
DO (1) DOP2012000127A (es)
EA (1) EA201200651A1 (es)
EC (1) ECSP12011878A (es)
ES (1) ES2487628T3 (es)
GT (1) GT201200138A (es)
IL (1) IL219113A0 (es)
MA (1) MA33721B1 (es)
MX (1) MX2012005293A (es)
MY (1) MY156209A (es)
NI (1) NI201200084A (es)
NZ (1) NZ599565A (es)
PE (1) PE20121471A1 (es)
TN (1) TN2012000153A1 (es)
TW (1) TW201139449A (es)
UY (1) UY33000A (es)
WO (1) WO2011054828A1 (es)
ZA (1) ZA201202530B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201391820A1 (ru) * 2011-06-09 2014-12-30 Новартис Аг Гетероциклические сульфонамидные производные
EP3549584A1 (en) 2013-03-12 2019-10-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer, and kras-mutant colon cancer
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN106518885B (zh) * 2016-10-26 2018-10-16 云南大学 1,3-二氮杂环并吡啶季铵盐类化合物及其中间体化合物、制备方法和应用
EP3752154A4 (en) * 2018-02-12 2021-12-29 Array Biopharma, Inc. Methods and combination therapy to treat biliary tract cancer
WO2019197605A2 (en) 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
BR9609617B1 (pt) 1995-07-06 2010-07-27 derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
BR9708640B1 (pt) 1996-04-12 2013-06-11 inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
JP2002513445A (ja) 1996-09-06 2002-05-08 オブデュキャット、アクチボラグ 導電材料内の構造の異方性エッチング方法
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CN1221262C (zh) 1999-03-30 2005-10-05 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
BR0116539A (pt) 2000-12-28 2003-09-23 Shionogi & Co Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AU2003211442A1 (en) 2002-02-19 2003-09-09 Shionogi And Co., Ltd. Antipruritics
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
KR20130058072A (ko) 2005-10-07 2013-06-03 엑셀리시스, 인코포레이티드 증식성 질환의 치료를 위한 ｍｅｋ 억제제로서의 아제티딘
DE602007009663D1 (de) 2006-04-18 2010-11-18 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek-hemmer
EA200900959A1 (ru) 2007-01-19 2010-02-26 Арди Байосайенсиз, Инк. Ингибиторы мек
US20090082328A1 (en) 2007-05-11 2009-03-26 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
JP5479337B2 (ja) 2007-07-30 2014-04-23 アルディア バイオサイエンス，インク． Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
TW201038267A (en) 2008-04-21 2010-11-01 Novartis Ag Heterocyclic compounds as MEK inhibitors
WO2009129938A1 (en) 2008-04-22 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted phenoxybenzamides
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
UY32486A (es) 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
CA2761108A1 (en) * 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors

Also Published As

Publication number Publication date
MY156209A (en) 2016-01-29
EP2496575B1 (en) 2014-04-30
CN102596951B (zh) 2015-04-15
TW201139449A (en) 2011-11-16
IL219113A0 (en) 2012-06-28
NI201200084A (es) 2012-08-13
AR078900A1 (es) 2011-12-14
US20110190334A1 (en) 2011-08-04
BR112012010519A2 (pt) 2017-12-05
KR101398772B1 (ko) 2014-05-27
CN102596951A (zh) 2012-07-18
MA33721B1 (fr) 2012-11-01
CA2779935A1 (en) 2011-05-12
CO6541547A2 (es) 2012-10-16
TN2012000153A1 (en) 2013-12-12
JP2013510118A (ja) 2013-03-21
AU2010317167A1 (en) 2012-05-03
JP5466767B2 (ja) 2014-04-09
EA201200651A1 (ru) 2012-12-28
AU2010317167B2 (en) 2012-11-29
UY33000A (es) 2011-06-30
US8466289B2 (en) 2013-06-18
ECSP12011878A (es) 2012-07-31
MX2012005293A (es) 2012-06-19
EP2496575A1 (en) 2012-09-12
KR20120090078A (ko) 2012-08-16
ES2487628T3 (es) 2014-08-22
GT201200138A (es) 2014-03-27
ZA201202530B (en) 2013-01-30
DOP2012000127A (es) 2012-08-31
CR20120234A (es) 2012-06-28
CL2012001027A1 (es) 2012-08-03
NZ599565A (en) 2013-05-31
WO2011054828A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20080315A1 (es) DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
SE0402735D0 (sv) Novel compounds
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20120107A1 (es) Inhibidores de proteina cinasa
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2012002179A (es) Compuestos heterociclicos de oxima.
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20141557A1 (es) Derivado de pirazoloquinolina
EA201270339A1 (ru) Замещенные производные ксантина
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NZ602041A (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
CY1121248T1 (el) Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων

Legal Events

Date Code Title Description
FD Application declared void or lapsed